Ketamine therapy provider HOPE Therapeutics announced it plans to acquire five ketamine clinics and reach $100 million in annual revenue in less than a year. HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), announced that it has secured $30 million in debt to finance the acquisitions. The company is apparently targeting five unspecified clinics in the Western U.S. HOPE Therapeutics also plans to expand its operations to France and the United Kingdom.
Read the full article: HOPE Therapeutics to Build $100M Ketamine Clinic Business via M&A //
Source: https://bhbusiness.com/2024/08/26/hope-therapeutics-to-build-100m-ketamine-clinic-business-via-ma